STOCK TITAN

Ultragenyx (RARE) director sells 2,000 shares at $25.05

(Neutral)
(Negative)
Form Type
4

Rhea-AI Filing Summary

Ultragenyx Pharmaceutical Inc. director Sanders Corazon (Corsee) D. sold 2,000 shares of Common Stock in an open-market transaction at $25.05 per share. After this sale, the director directly holds 21,095 shares. The reported holdings include previously disclosed RSUs that will vest over time.

Positive

  • None.

Negative

  • None.
Insider Sanders Corazon (Corsee) D.
Role Director
Sold 2,000 shs ($50K)
Type Security Shares Price Value
Sale Common Stock 2,000 $25.05 $50K
Holdings After Transaction: Common Stock — 21,095 shares (Direct)
Footnotes (1)
  1. [object Object]
Shares sold 2,000 shares Open-market sale of Common Stock
Sale price $25.05 per share Price for the 2,000 shares sold
Shares held after sale 21,095 shares Direct ownership after transaction
Net shares sold 2,000 shares Net-sell direction in this filing
open-market sale financial
"executed an open-market sale of 2,000 shares of Common Stock"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Common Stock financial
"sold 2,000 shares of Common Stock in an open-market transaction"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
RSUs financial
"includes previously reported shares of common stock underlying RSUs granted"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
vesting conditions financial
"RSUs granted to the Reporting Person, which are subject to certain vesting conditions"
Vesting conditions are the rules that determine when someone earning company stock or stock options actually gains the right to keep or sell them, typically based on staying with the company for a set time or meeting performance targets. Think of it like keys that unlock gradually — some unlock by calendar date, others only after agreed milestones. Investors care because vesting shapes management incentives, the timing of share sales, and the number of shares that can enter the market, which can affect a company's valuation and ownership mix.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Ultragenyx (RARE) disclose for Sanders Corazon (Corsee) D.?

Ultragenyx reported that director Sanders Corazon (Corsee) D. executed an open-market sale of 2,000 shares of Common Stock. The transaction was recorded as a sale at a specified market price on the reported date.

How many Ultragenyx (RARE) shares did the director sell and at what price?

The director sold 2,000 shares of Ultragenyx Common Stock at $25.05 per share. This was an open-market sale, meaning the shares were sold through normal trading on the market rather than via a private agreement.

How many Ultragenyx (RARE) shares does the director hold after this sale?

Following the sale, the director directly holds 21,095 shares of Ultragenyx Common Stock. This post-transaction figure includes previously reported shares underlying restricted stock units that are subject to vesting conditions over time.

Does the Ultragenyx (RARE) filing mention RSUs for the reporting person?

Yes. The filing notes that the reported holdings include shares underlying restricted stock units granted to the reporting person. These RSUs are subject to specific vesting conditions before they become fully owned shares of Common Stock.

Was the Ultragenyx (RARE) insider trade classified as an open-market sale?

Yes. The transaction is coded as an open-market sale of Common Stock. This indicates the shares were sold through regular trading channels, rather than through a private transaction or internal company program.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sanders Corazon (Corsee) D.

(Last)(First)(Middle)
C/O ULTRAGENYX PHARMACEUTICAL INC.
60 LEVERONI COURT

(Street)
NOVATO CALIFORNIA 94949

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Ultragenyx Pharmaceutical Inc. [ RARE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/15/2026S2,000D$25.0521,095(1)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
/s/ Karah Parschauer, attorney-in-fact06/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)